Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 33,219 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Other Disease Clear all

Conditions: Ovarian Cancer
Interventions: ABBV-901, Bevacizumab, Carboplatin; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 8
States / cities: Duarte, California • Irvine, California • Denver, Colorado + 5 more

Conditions: Childhood Cancer, Cerebral Palsy, Chronic Lung Disease, Congenital Heart Disease, Congenital Metabolic Disorder, Gastrostomy
Interventions: GoalKeeper, Standard Care; Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Breast Cancer Metastatic
Interventions: Avasopasem; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Supraventricular Tachycardia
Interventions: New Ablation Technique, Standard Ablation Technique; Procedure
Lead sponsor: Jeffrey Moak; Other
Eligibility: Up to 21 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 5
States / cities: Washington D.C., District of Columbia • Hollywood, Florida • Iowa City, Iowa + 2 more

Conditions: Non-Hodgkin's Lymphoma, Hodgkin's Disease
Interventions: SB-743921; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 6
States / cities: Hackensack, New Jersey • New York, New York • Chapel Hill, North Carolina + 1 more

Conditions: Meningococcal Disease
Interventions: MenACWY-CRM; Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 11 Years to 21 Years
Enrollment: 55,397 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 3
States / cities: Riverside, California • San Diego, California • Valley Annex, 16994 E. Valley Blvd., Fontana, California

Conditions: Delirium, Cognition Disorders
Interventions: Ziprasidone, Haloperidol, Placebo; Drug · Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 5
States / cities: Iowa City, Iowa • Chapel Hill, North Carolina • Greensboro, North Carolina + 1 more

Conditions: Metastatic Cancer, Solid Tumors, Colorectal Cancer (CRC), Gastric Cancer, Head and Neck Cancer, Lung Cancer, Renal Cell Carcinoma (RCC), Bladder Cancer, UC (Urothelial Cancer), Mesothelioma
Interventions: INCB001158, Pembrolizumab; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 13
States / cities: Mobile, Alabama • Scottsdale, Arizona • Tucson, Arizona + 7 more

Conditions: Ulcerative Colitis
Interventions: Amg 181; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 4
States / cities: Glendale, California • Danbury, Connecticut • Plymouth, Minnesota + 1 more

Conditions: Low Back Pain
Interventions: ED Physical Therapy, Usual Care; Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Early NIPPV, Standard NIPPV; Device
Lead sponsor: Edward Kasaraskis; Other
Eligibility: 18 Years to 80 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 12
States / cities: Denver, Colorado • Miami, Florida • Lexington, Kentucky + 8 more

Conditions: Primary Progressive Multiple Sclerosis, Primary Progressive MS, Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive MS (SPMS), Secondary Progressive Multiple Sclerosis (SPMS), Secondary Progressive MS, Non-Active SPMS, Non-Active Secondary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis With Inflammatory Disease Activity
Interventions: SUN-627, Placebo; Drug · Other
Lead sponsor: Sundance Biosciences, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 7
States / cities: Tampa, Florida • Atlanta, Georgia • Stony Brook, New York + 4 more

Conditions: Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndrome
Interventions: atorvastatin, Tacrolimus, methotrexate; Drug
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Pneumonia, Ventilator-associated, Pneumonia, Staphylococcal
Interventions: ASN100, Placebo; Drug
Lead sponsor: Arsanis, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 17
States / cities: Phoenix, Arizona • Sacramento, California • San Francisco, California + 13 more

Conditions: Blood and Blood Disorders, Anemia, Neonatal, Hematologic Disease, Infant, Newborn, Diseases
Interventions: Fetoscopic laser surgery; Procedure
Lead sponsor: Assistance Publique - Hôpitaux de Paris; Other
Eligibility: 18 Years and older · Female only
Enrollment: 179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 8
States / cities: Aurora, Colorado • Baltimore, Maryland • Cincinnati, Ohio + 5 more

Conditions: Endometrial Cancer
Interventions: retifanlimab, epacadostat, pemigatinib, INCAGN02385, INCAGN02390; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 29
States / cities: Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 26 more

Conditions: Fibrodysplasia Ossificans Progressiva
Interventions: Palovarotene; Drug
Lead sponsor: Clementia Pharmaceuticals Inc.; Industry
Eligibility: 4 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 4
States / cities: San Francisco, California • Rochester, Minnesota • Philadelphia, Pennsylvania

Conditions: Schizophrenia, Autism Spectrum Disorder
Interventions: Oxytocin, Placebo Comparator; Drug · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 75 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Idiopathic Parkinson's Disease
Interventions: apomorphine infusion; Drug
Lead sponsor: MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals; Industry
Eligibility: 30 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 18
States / cities: Phoenix, Arizona • Loma Linda, California • Los Angeles, California + 13 more

Conditions: Prostatic Neoplasms
Interventions: Registry; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Male only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Bronchopulmonary Dysplasia, Bronchopulmonary Dysplasia Associated Pulmonary Hypertension, Pulmonary Hypertension, Premature Birth, Chronic Lung Disease of Prematurity
Interventions: Enteral L-citrulline; Dietary Supplement
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: Up to 30 Weeks
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: End-Stage Renal Disease (ESRD)
Interventions: EPN-701 (Oral); Drug
Lead sponsor: Epizon Pharma, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Hospital Acquired Condition
Interventions: CONCERN CDS system notification; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 60,893 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 4
States / cities: Boston, Massachusetts • Newton, Massachusetts • New York, New York

Conditions: Post-Acute COVID-19 Syndrome
Interventions: NeuroFlex (computerized gamified tasks); Other
Lead sponsor: UConn Health; Other
Eligibility: 60 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Farmington, Connecticut

Search by objective public record fields.

A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer

GoalKeeper: Intelligent Information Sharing for Children With Medical Complexity

Clinical Trial of Avasopasem in Patients With Metastatic Hormone Receptor Positive Breast Cancer With Progression on a CDK 4/6 Inhibitor and Hormonal Therapy

Treatment Study of AV Node Reentry Tachycardia

A Study of SB-743921 in Non-Hodgkin Lymphoma and Hodgkin Lymphoma

Safety of MenACWY-CRM Vaccination in Adolescents

The MIND Study: Modifying the INcidence of Delirium

Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181 in Healthy Subjects and Subjects With Mild to Moderate Ulcerative Colitis

ED Physical Therapy for Acute Low Back Pain

Early Treatment of Amyotrophic Lateral Sclerosis (ALS) With Nutrition and Non-Invasive Positive Pressure Ventilation

A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)

Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation

Prevention of S. Aureus Pneumonia Study in Mechanically Ventilated Subjects Who Are Heavily Colonized With S. Aureus.

Randomized Controlled Trial Comparing a Conservative Management and Laser Surgery

Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.

An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva.

Dyad Oxytocin Study (DOS)

Infusion of Apomorphine: Long-term Safety Study

An Electronic Registry to Improve Adherence to Active Surveillance Monitoring at a Safety-net Hospital

Enteral L Citrulline Supplementation in Preterm Infants - Safety, Efficacy and Dosing

A Clinical Trial of Epizon-701 (EPN-701) in Subjects With End-Stage Renal Disease (ESRD)

(CONCERN) Clinical Decision Support (CDS) System

Brain-Training Treatment for Long COVID in Older Adults